A-Alpha Bio, Inc.
Machine learning platform trained on high-throughput antibody-antigen binding datasets to predict therapeutic potency of antibody therapies against viral variants
- Sector
- Biotech
- Headquarters
- SEATTLE, WA
- Founded
- 2017
- Latest Form D
- $20.3M, Sep 2021
- Total capital
- $24.8M
- Federal grants
- $1.7M
- 3 awards · 2018–2020
- Rank in peer group#19 of 37
- Private capital raised
- $23.1M
- 2 Form D · last Sep 2021
- 62 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 6
- 29 pending · first 2022
- Rank in peer group#3 of 37
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$20.3M
- Federal grantNSF · Phase I · SBIR Phase I: Developing a Rapid Antibody Generation Platform for Emerging COVID-19 Variants$256K
- Federal grantNSF · Phase II · SBIR Phase II: Developing a Platform for Multiplexed Drug Profiling Using Yeast Synthetic Agglutination$1.2M
- Private capital raisedForm D · SEC · 1st filing$2.8M
- Federal grantNSF · Phase I · SBIR Phase I: Developing a Platform for Multiplexed Drug Profiling Using Yeast Synthetic Agglutination$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
16months
from A-Alpha Bio, Inc.’s first federal award to its first private round.
- First federal award · Jun 2018
- NSF · $225K
- First Form D · Sep 2019
- $2.8M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 37 peers
Line = medianBiotech · Platform
- Federal grants#19 · top 51%
- Granted patents#3 · top 8%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- David YoungerResearcherExecutive Officer, DirectorLinked by 2 patents · $1.4M in grants as PI
- Randolph Lopez BarrezuetaResearcherDirectorLinked by $256K in grants as PI
- Ben AskewDirectorNamed in SEC Form D filings
- Matt McIlwainDirectorNamed in SEC Form D filings
What it has protected
USPTO · 6 granted of 35- PendingMethod For Characterizing And Engineering Protein-protein InteractionsUSPTOApplication 19302361
- PendingHigh-throughput Screening Methods To Identify Small Molecule TargetsUSPTOApplication 19299982
- PendingSynthetic Augmentation of Multiple Sequence Alignment of Protein-Protein InteractionsUSPTOApplication 19224703
Show all 35 patent records
- Method For Characterizing And Engineering Protein-protein InteractionsMar 19, 2026 · Application 19302361Pending
- High-throughput Screening Methods To Identify Small Molecule TargetsMar 12, 2026 · Application 19299982Pending
- Synthetic Augmentation of Multiple Sequence Alignment of Protein-Protein InteractionsDec 4, 2025 · Application 19224703Pending
- Interferon ALPHA-2 VariantsSep 23, 2025 · US 12,421,288Granted
- Efficiently Characterizing Protein-protein InteractionsJul 10, 2025 · Application 19013642Pending
- Digital Counting Of Cell Fusion Events Using Dna BarcodesMay 29, 2025 · Application 18833072Pending
- Interleukin 21 VariantsApr 22, 2025 · US 12,281,147Granted
- Efficiently Characterizing Protein-protein InteractionsFeb 18, 2025 · US 12,230,363Granted
- High-Throughput Screening Methods to Identify Small Molecule TargetsJan 14, 2025 · US 12,195,730Granted
- Methods For Identifying Protein Coding Sequences Using Dna BarcodesOct 31, 2024 · Application 18291791Pending
- Methods For Identifying Protein Coding Sequences Using Dna BarcodesSep 19, 2024 · Application 18423075Pending
- Methods For Characterizing And Engineering Protein-protein InteractionsAug 15, 2023 · US 11,726,097Granted
- High-Throughput Screening Methods to Identify Small Molecule TargetsDec 1, 2022 · Application 17607801Pending
- High-Throughput Screening Methods to Identify Small Molecule TargetsOct 11, 2022 · US 11,466,265Granted
- Methods For Characterizing And Engineering Protein-protein InteractionsAug 11, 2022 · Application 17619506Pending
- Methods For Characterizing And Engineering Protein- Protein InteractionsApplication PCTUS2021035246Pending
- High-throughput Screening Methods To Identify Small Molecule TargetsApplication PCTUS2021027111Pending
- Methods for Characterizing and Engineering Protein-Protein InteractionsApplication 63033176Pending
- High-Throughput Screening Methods to Identify Small Molecule TargetsApplication 63023181Pending
- Interferon ALPHA-2 VariantsApplication 19165482Pending
- Interleukin 21 VariantsApplication 19510943Pending
- Synthetic Augmentation Of Multiple Sequence Alignment Of Protein-protein InteractionsApplication PCTUS2025031781Pending
- Interleukin 21 VariantsApplication PCTUS2024042270Pending
- Synthetic Augmentation Of Multiple Sequence Alignment Of Protein-protein InteractionsApplication 63654840Pending
- Interleukin 21 VariantsApplication 63574538Pending
- Interferon ALPHA-2 VariantsApplication PCTUS2024020211Pending
- Efficiently Characterizing Protein-protein InteractionsApplication PCTUS2023037104Pending
- Interleukin 21 VariantsApplication 63519389Pending
- Interferon ALPHA-2 VariantsApplication 63497089Pending
- Interferon ALPHA-2 VariantsApplication 63452654Pending
- Digital Counting Of Cell Fusion Events Using Dna BarcodesApplication PCTUS2023011768Pending
- Efficiently Characterizing Protein-protein InteractionsApplication 63424382Pending
- Methods For Identifying Protein Coding Sequences Using Dna BarcodesApplication PCTUS2022043139Pending
- Digital Counting Of Cell Fusion Events Using Dna BarcodesApplication 63304380Pending
- Methods for Identifying Protein Coding Sequences Using DNA BarcodesApplication 63244957Pending
Related companies, and why
- GeniPhys, LLCSimilar federal contract value in Biotech · null in contracts
- Betula Extractives, LLC.Similar federal contract value in Biotech · null in contracts
- Sepragen CorporationSimilar federal contract value in Biotech · null in contracts
- Odorcept, LLCSimilar federal contract value in Biotech · null in contracts
- ALTAY THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Elektrofi IncSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .